Floatz logo

Ricolinostat

Lymphoid Malignancies

Jennifer AmengualSmall moleculePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Lymphoid Malignancies cohort.

View all 33

Same molecule, other indications

Ricolinostat is also rated in:

diabetic polyneuropathyDormant
CCC
Indicative ·
52 / 100
View asset →
plasma cell myelomaDormant
CCC
Indicative ·
48 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →